

FORM PTO-1449		O P E SEP 05 2001 TRADEMA		SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.					

REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
W	A1 3,031,450	4/24/62	Fischer et al.		
	A2 3,161,654	12/15/64	Shen		
	A3 3,312,730	4/4/67	Winter et al.		
	A4 3,322,755	5/30/67	Roch et al.		
	A5 3,325,358	6/13/67	Winter et al.		
	A6 3,532,752	10/6/70	Shen		
	A7 3,642,785	2/15/72	Shen et al.		RECEIVED OCT 16 2001
	A8 3,647,858	3/7/72	Hinkley et al.		
	A9 3,654,349	4/4/72	Shen et al.	TECH CENTER 1600/2900	
	A10 3,692,651	9/19/72	Sletzinger et al.		
	A11 3,692,825	9/19/72	Conn		
W	A12 3,737,455	6/5/73	Shen et al.		
	A13 3,851,063	11/26/74	Shen et al.		

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
W	A14 EP 0 293 063 B1	3/18/92	EPO		
	A15 EP 0 347 146 B1	9/1/93	EPO		
	A16 EP 0 349 239 A2	1/3/90	EPO		
W	A17 EP 0 352 960 B1	10/26/94	EPO		
	A18 EP 0 351 058 B1	6/2/93	EPO		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
W	A19	Ahmad F. et al., IL-3 ad IL-4 Activate Cyclic Nucleotide Phosphodiesterases 3 (PDE3) and 4 (PDE4) by Different Mechanisms in FDCP2 Myeloid Cells, J. Immunology Vol. 162, Part 8, pp. 4864-4875 (Apr 15 1999).
W	A20	Boven LA et al., Macrophage inflammatory protein-1 alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions, Clin. Exp. Immunol. 2000 Nov.; 122(2): 257-63 (Abstract Only).
W	A21	Cooper N. et al., A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo, British Journal of Pharmacology (1999) 126, pp. 1863-1871.
W	A22	Czirjak L. et al., Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis, Clin Rheumatology 1999; 18(5), pp. 357-363 (Abstract Only).
W	A23	Danahay H. et al., PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs, Clinical and Experimental Allergy, 1998, Vol. 28, pp. 513-522.
W	A24	Duggan, D.E. et al., Identification of the Biologically Active Form of Sulindac, J. Pharm. & Exper. Therap., Vol. 201, No. 1, pp.8-13 (1977).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449



**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT**
(use several sheets if necessary)

SERIAL NO.	CASE NO.
09/938,160	P-191
FILING DATE	GROUP ART UNIT
AUGUST 23, 2001	NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
✓	A25 3,860,636	11/14/75	Shen et al.		
	A26 4,402,979	9/6/83	Shen et al.		
	A27 4,307,114	12/22/81	Dvornik et al.		
	A28 4,423,074	12/27/83	Dvornik et al.		
	A29 4,423,075	12/27/83	Dvornik et al.		
	A30 4,880,810	11/14/89	Lowe, III		
	A31 4,885,301	12/5/89	Coates		OCT 16 2001
	A32 5,298,525	3/29/94	Yoon et al.		
	A33 5,401,774	3/28/95	Pamukcu et al.		TECH CENTER 1600/2900
	A34 5,470,873	11/28/95	Yoon		
✓	A35 5,488,055	1/30/96	Kumar et al.		
✓	A36 5,527,896	6/18/96	Wigler et al.		
✓	A37 5,602,019	2/11/97	Beavo et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
✓	A38 EP 0 395 328 A2	10/31/90	EPO		
	A39 EP 0 428 268 A2	5/22/91	EPO		
✓	A40 EP 0 463 756 A1	1/2/92	EPO		
✓	A41 EP 0 526 004 A1	2/3/93	EPO		
✓	A42 EP 0 722 943 A1	1/8/96	EPO		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
✓	A43	Gantner F. et al., Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function, <i>Pulmonary Pharmacology & Therapeutics</i> (1999) 12, pp. 377-386.
✓	A44	Gantner F. et al., In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor- α release by PDE inhibitors, <i>British Journal of Pharmacology</i> (1997) 121, pp. 221-231.
✓	A45	Gehrman J. et al., Amyloid precursor protein (APP) expression in multiple sclerosis lesions, <i>Glia</i> 1995 Oct;15(2), pp. 141-151 (Abstract Only).
✓	A46	Germain N. et al., Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs, <i>Eur. Respir. J.</i> 1998;12, pp. 1334-1339.
✓	A47	Giembusz, M.A., Phosphodiesterase 4 Inhibitors and the Treatment of Asthma, <i>Drugs 2000</i> Feb; 59(2), pp. 193-212.
✓	A48	Gonzaga, R.A.F. et al., The Lancet, 3/30/85, p. 751.

EXAMINER	DATE CONSIDERED
✓	6/5/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449



LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.	09/938,160	CASE NO.
FILING DATE	AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.		

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
W	A49 5,602,171	2/11/97	Tang et al.		
	A50 5,614,530	3/25/97	Kumar et al.		
	A51 5,614,627	3/25/97	Takase et al.		
	A52 5,708,022	1/13/98	Bastos et al.		
	A53 5,776,752	7/7/98	Beavo et al.		
	A54 5,789,553	8/4/98	Beavo et al.		
	A55 5,798,374	8/25/98	Tang et al.		
	A56 5,800,987	9/1/98	Beavo et al.		
	A57 5,852,035	12/22/98	Pamukcu et al.		
	A58 5,858,694	1/12/99	Piazza et al.		
	A59 5,861,396	1/19/99	Niewöhner et al.		
	A60 5,874,440	2/23/99	Pamukcu et al.		
W	A61 5,883,110	3/16/99	Tang et al.		

RECEIVED

OCT 16 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
W	EP 0 722 944 A1	1/8/96	EPO		
	EP 1 074 258 A3	4/18/01	EPO		
	GB 807,826	1/21/59	United Kingdom		
W	GB 2 063 249 A	6/3/81	United Kingdom		
W	HEI 8-311035	11/26/96	Japan		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
W	A67	Hammermann, R. et al., Phosphodiesterase Inhibitors and Forskolin Up-regulate Arginase Activity in Rabbit Alveolar Macrophages, Pulmonary Pharmacology and Therapeutics 2000; Vol. 13, No. 3, pp. 141-147.
W	A68	He W. et al., Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors, J. Med. Chem., Vol. 41, Part 22, pp. 4216-4223 (Oct 22 1998)
W	A69	Hollander AP et al., Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint, Arthritis Rheum. 2001 Jul; 44(7): 1540-4 (Abstract Only).
W	A70	Imahashi K. et al., Type IV Phosphodiesterase Inhibitor Suppresses Insulin-Dependent Myocardial Glucose Uptake, Clin Exp Pharmacol Physiol 2001 Apr;28(4), pp. 290-291 (Abstract Only)
W	A71	Ishikawa O. et al., Macrophage infiltration in the skin of patients with systemic sclerosis, J. Rheumatology 1992 Aug; 19(8), pp. 1202-1206 (Abstract Only).
W	A72	Kapur S. et al., Expression of Nitric Oxide Synthase in Skeletal Muscle, Diabetes, Vol. 46, Nov. 1997, pp. 1691-1700.

EXAMINER	DATE CONSIDERED
W	10/10/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SEP 05 2001	SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.			

REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
W	A73 5,885,834	3/23/99	Epstein		
	A74 5,902,827	5/11/99	Pamukcu et al.		
	A75 5,922,595	7/13/99	Fisher et al.		
	A76 5,942,520	8/24/99	Pamukcu et al.		
	A77 5,948,911	9/7/99	Pamukcu et al.		
	A78 5,958,982	9/28/99	Pamukcu et al.		
	A79 5,990,117	11/23/99	Pamukcu et al.		
	A80 5,998,463	12/7/99	Hulin et al.		
	A81 6,008,215	12/28/99	Flockerzi		
	A82 6,015,677	1/18/00	Beavo et al.		
	A83 6,034,099	3/7/00	Pamukcu et al.		
	A84 6,037,345	3/14/00	Pamukcu et al.		
W	A85 6,046,199	4/4/00	Pamukcu et al.		

RECEIVED

OCT 16 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
W	A86 SHO 61-106521	5/24/86	Japan		
	A87 WO 01/04099 A1	1/18/01	PCT		
	A88 WO 00/12501	3/9/00	PCT		
	A89 WO 00/26201	5/11/00	PCT		
	A90 WO 00/23091	4/27/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
W	A91	Kelly J. et al., Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors, British Journal of Pharmacology (1998) 124, PP. 129-140.
W	A92	Kelly J. et al., Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [³ H]R-(–)-rolipram binding by selective inhibitors, Biochem. J. (1996) 318, pp. 425-436.
W	A93	Kumar A. et al., Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors, Indian J Exp Biol 2000 Jan;38(1), pp. 26-30 (Abstract Only)
W	A94	Lee MS et al., A comparative immunohistochemical study of lichen planus and discoid lupus erythematosus, Australas J. Dermatol. 1996 Nov.; 37(4): 188-92 (Abstract Only).
W	A95	McPherson M.A. et al., A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein, FEBS Letters 464 (1999), pp. 48-52.
W	A96	Mery P.F. et al., Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes, Mol. Pharmacology 1995 Jul;48(1), pp. 121-130 (Abstract Only)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO.	CASE NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	09/938,160	P-191
	FILING DATE	GROUP ART UNIT NOT YET ASSIGNED
	AUGUST 23, 2001	
	APPLICANT(S): WHITEHEAD ET AL.	



REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
W	A97 6,046,206	4/4/00	Pamukcu et al.		
	A98 6,046,216	4/4/00	Piazza et al.		
	A99 6,060,477	5/9/00	Piazza et al.		
	A100 6,066,634	5/23/00	Sperl et al.		
	A101 6,069,240	5/30/00	Wigler et al.		
	A102 6,071,934	6/6/00	Sperl et al.		
	A103 6,077,842	6/20/00	Pamukcu et al.		
	A104 6,080,540	6/27/00	Wigler et al.		
	A105 6,080,742	6/27/00	Germann et al.		
	A106 6,080,772	6/27/00	Tang et al.		
	A107 6,100,025	8/8/00	Wigler et al.		
W	A108 6,107,295	8/22/00	Rochus et al.		
W	A109 6,124,303	9/26/00	Pamukcu et al.		

RECEIVED

OCT 16 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
W	A110 WO 00/26208	5/11/00	PCT		
	A111 WO 00/27861	5/18/00	PCT		
	A112 WO 00/42017	7/20/00	PCT		
	A113 WO 00/42018	7/20/00	PCT		
W	A114 WO 00/42019	7/20/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
W	A115 Méry, Pierre-François et al., EHNA as an Inhibitor of PDE2: A Pharmacological and Biochemical Study in Cardiac Myocytes, Phosphodiesterase Inhibitors (1996), pp. 81-88.
W	A116 Michie, A.M. et al., Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram, Cell Signal 1996 Feb;8(2), pp. 97-110.
W	A117 Niebauer J. et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Circulation 1999;100, pp. 1830-1835.
W	A118 Odoux C. et al., Endothelin-1 secretion by alveolar macrophages in systemic sclerosis, Am. J. Respir. Crit. Care Med. 1997 Nov;156(5), pp. 1429-1435 (Abstract Only).
W	A119 Ostensen M. et al., Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus, Lupus (2001) 10, pp. 135-139.
W	A120 Piazza G.A. et al., Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis, Cancer Research 55, Jul 15 1995, pp. 3110-3116.

EXAMINER <i>W</i>	DATE CONSIDERED <i>6/5/05</i>
-------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.			

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
✓	A121 6,133,271	10/17/00	Pamukcu et al.		
	A122 6,143,746	11/7/00	Daugan et al.		
	A123 6,143,759	11/7/00	Flockerzi		
	A124 6,143,765	11/7/00	Tang et al.		
	A125 6,143,777	11/7/00	Jonas et al.		
	A126 6,169,090	1/2/01	Dyke et al.		
	A127 6,174,884	1/16/01	Haning et al.		
	A128 6,187,779	2/13/01	Pamukcu et al.		
	A129 6,200,771	3/13/01	Liu et al.		
	A130 6,200,980	3/13/01	Piazza et al.		
	A131 6,207,666	3/27/01	Piazza et al.		
✓	A132 6,211,177	4/3/01	Sperl et al.		
✓	A133 6,211,220	4/3/01	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
✓	A134 WO 00/42034	7/20/00	PCT		
	A135 WO 00/59890	10/12/00	PCT		
✓	A136 WO 00/64424	11/2/00	PCT		
✓	A137 WO 99/65880	11/23/99	PCT		
✓	A138 WO 98/19679A1	5/14/98	PCT (Claims Only)		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
✓	A139	Reis E. et al., Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice, PNAS 97(23): pp. 12764-12769. 1999
✓	A140	Rice P.L. et al., Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites, Cancer Research 2001, Feb 15;61(4), pp. 1541-1547 (Abstract Only).
✓	A141	Soh, Jae-Won et al., Cyclic GMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of c-Jun NH ₂ -Terminal Kinase 1, Clinical Cancer Research Vol. 6, pp. 4136-4141, October 2000.
✓	A142	Soh, Jae-Won et al., Protein Kinase G Activates the JNK1 Pathway via Phosphorylation of MEKK1, The Journal of Biological Chemistry, Vol. 276, No. 19, pp. 16406-16410 (2001).
✓	A143	Thompson, W.J. et al., Exisulind Induction of Apoptosis Involves Guanosine 3',5'-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated β -Catenin, Cancer Research 60, pp. 3338-3342, July 1, 2000.
✓	A144	Tien, Xiao-Ying, et al., Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by cGMP in the Human Colonic Cancer Cell Line, Caco-2, The Journal of Biological Chemistry, Vol. 269, No. 1, pp. 51-54 (1994).

EXAMINER	DATE CONSIDERED
✓	6/5/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SEP 8 2001 U.S. PATENT AND TRADEMARK OFFICE	SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.			

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
✓	A155 WO 98/17668	4/30/98	PCT			
	A156 WO 98/14448	4/9/98	PCT			
	A157 WO 98/06722	2/19/98	PCT			
	A158 WO 97/24334	7/10/97	PCT			
✓	A159 WO 97/03985	2/6/97	PCT			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
<input checked="" type="checkbox"/>	A160	Tsukahara T et al., Cytophagic histiocytic panniculitis in systemic lupus erythematosus, Hiroshima J. Med. Sci., 1995 Mar; 44(1): 13-6 (Abstract Only).
<input checked="" type="checkbox"/>	A161	Waddel W. R. et al., Sulindac for Polyposis of the Colon, The American Journal of Surgery, Vol. 157, Jan. 1989, pp. 175-179.
<input checked="" type="checkbox"/>	A162	Waddel W. R. et al., Sulindac for Polyposis of the Colon, Journal of Surgical Oncology, 24: pp. 83-87 (1983).
<input checked="" type="checkbox"/>	A163	Weyand CM and Goronzy JJ, HLA polymorphisms and T cells in rheumatoid arthritis, Int. Rev. Immunol. 1999, 19(1-2):37-39 (Abstract Only).
<input checked="" type="checkbox"/>	A164	Wilder R.L. et al., Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus?, Ann. NY Acad. Sci 1999 June 22:876, pp. 14-31 (Abstract Only).

EXAMINER  DATE CONSIDERED 6/5/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next
communication to applicant.



FORM PTO-1449	SERIAL NO.	CASE NO.
SEP 05 2001		09/938,160 P-191
LIST OF PATENTS AND PUBLICATIONS FOR: APPLICANT'S INFORMATION DISCLOSURE STATEMENT		
(use several sheets if necessary)		
FILING DATE	GROUP ART UNIT	
AUGUST 23, 2001		NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.		

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

RECEIVED

OCT 16 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
JK	A165 WO 97/03675	2/6/97	PCT			
JK	A166 WO 94/29277	11/22/94	PCT			
JK	A167 WO 93/07149	4/15/93	PCT			

EXAMINER *[Signature]* DATE CONSIDERED 6/5/65

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next
communication to applicant.

FORM PTO-1449

NOV 19 2003

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A1	3,031,450	4/24/62	Fischer et al.		
A2	3,161,654	12/15/64	Shen		
A3	3,312,730	4/4/67	Winter et al.		
A4	3,322,755	5/30/67	Roch et al.		
A5	3,325,358	6/13/67	Winter et al.		
A6	3,532,752	10/6/70	Shen		
A7	3,642,785	2/15/72	Shen et al.		
A8	3,647,858	3/7/72	Hinkley et al.		
A9	3,654,349	4/4/72	Shen et al.		
A10	3,692,651	9/19/72	Sletzinger et al.		
A11	3,692,825	9/19/72	Conn		
A12	3,737,455	6/5/73	Shen et al.		
A13	3,851,063	11/29/74	Shen et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	TRANSLATION NO
A14	EP 0 293 063 B1	3/18/92	EPO			
A15	EP 0 347 146 B1	9/1/93	EPO			
A16	EP 0 349 239 A2	1/3/90	EPO			
A17	EP 0 352 960 B1	10/26/94	EPO			
A18	EP 0 351 058 B1	6/2/93	EPO			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
A19	Ahmad F. et al., IL-3 and IL-4 Activate Cyclic Nucleotide Phosphodiesterases 3 (PDE3) and 4 (PDE4) by Different Mechanisms in FDCP2 Myeloid Cells, <i>J. Immunology</i> Vol. 162, Part 8, pp. 4864-4875 (Apr 15 1999).
A20	Boven LA et al., Macrophage inflammatory protein-1 alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions, <i>Clin. Exp. Immunol.</i> 2000 Nov.; 122(2): 257-63 (Abstract Only).
A21	Cooper N. et al., A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo, <i>British Journal of Pharmacology</i> (1999) 126, pp. 1863-1871.
A22	Czirjak L. et al., Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis, <i>Clin Rheumatology</i> 1999; 18(5), pp. 357-363 (Abstract Only).
A23	Danahay H. et al., PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs, <i>Clinical and Experimental Allergy</i> , 1998, Vol. 28, pp. 513-522.
A24	Duggan, D.E. et al., Identification of the Biologically Active Form of Sulindac, <i>J. Pharm. & Exper. Therap.</i> , Vol. 201, No. 1, pp. 8-13 (1977).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

NOV 19 2003
 LIST OF PATENTS AND PUBLICATIONS FOR
 APPLICANT'S INFORMATION DISCLOSURE STATEMENT
 (use several sheets if necessary)

SERIAL NO.	09/938,160	CASE NO.
FILING DATE	AUGUST 23/2001	GROUP ART UNIT P-191
		NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A25 3,860,636	11/14/75	Shen et al.		
	A26 4,402,979	9/6/83	Shen et al.		
	A27 4,307,114	12/22/81	Dvornik et al.		
	A28 4,423,074	12/27/83	Dvornik et al.		
	A29 4,423,075	12/27/83	Dvornik et al.		
	A30 4,880,810	11/14/89	Lowe, III		
	A31 4,885,301	12/5/89	Coates		
	A32 5,298,525	3/29/94	Yoon et al.		
	A33 5,401,774	3/28/95	Pamukcu et al.		
	A34 5,470,873	11/28/95	Yoon		
	A35 5,488,055	1/30/96	Kumar et al.		
	A36 5,527,896	6/18/96	Wigler et al.		
	A37 5,602,019	2/11/97	Beavo et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A38 EP 0 395 328 A2	10/31/90	EPO		
	A39 EP 0 428 268 A2	5/22/91	EPO		
	A40 EP 0 463 756 A1	1/2/92	EPO		
	A41 EP 0 526 004 A1	2/3/93	EPO		
	A42 EP 0 722 943 A1	1/8/96	EPO		US 5,866,571

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A43	Gantner F. et al., Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function, Pulmonary Pharmacology & Therapeutics (1999) 12, pp. 377-386.
	A44	Gantner F. et al., In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor- α release by PDE inhibitors, British Journal of Pharmacology (1997) 121, pp. 221-231.
	A45	Gehrmann J. et al., Amyloid precursor protein (APP) expression in multiple sclerosis lesions, Glia 1995 Oct;15(2), pp. 141-151 (Abstract Only).
	A46	Germain N. et al., Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs, Eur. Respir. J. 1998;12, pp. 1334-1339.
	A47	Giembycz, M.A., Phosphodiesterase 4 Inhibitors and the Treatment of Asthma, Drugs 2000 Feb; 59(2), pp. 193-212.
	A48	Gonzaga, R.A.F. et al., The Lancet, 3/30/85, p. 751.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

NOV 19 2003

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.	09/938,160	CASE NO.
FILING DATE	AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S):	WHITEHEAD ET AL.	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A49	5,602,171	2/11/97	Tang et al.		
A50	5,614,530	3/25/97	Kumar et al.		
A51	5,614,627	3/25/97	Takase et al.		
A52	5,708,022	1/13/98	Bastos et al.		
A53	5,776,752	7/7/98	Beavo et al.		
A54	5,789,553	8/4/98	Beavo et al.		
A55	5,798,374	8/25/98	Tang et al.		
A56	5,800,987	9/1/98	Beavo et al.		
A57	5,852,035	12/22/98	Pamukcu et al.		
A58	5,858,694	1/12/99	Piazza et al.		
A59	5,861,396	1/19/99	Niewöhner et al.		
A60	5,874,440	2/23/99	Pamukcu et al.		
A61	5,883,110	3/16/99	Tang et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
A62	EP 0 722 944 A1	1/8/96	EPO	→ US 5,861,404	
A63	EP 1 074 258 A3	4/18/01	EPO	→ US 2001 0119974 A1	
A64	GB 807,826	1/21/59	United Kingdom		
A65	GB 2 063 249 A	6/3/81	United Kingdom		
A66	HEI 8-311035	11/26/96	Japan		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
A67	Hammermann, R. et al., Phosphodiesterase Inhibitors and Forskolin Up-regulate Arginase Activity in Rabbit Alveolar Macrophages, Pulmonary Pharmacology and Therapeutics 2000; Vol. 13, No. 3, pp. 141-147.	
A68	He W. et al., Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors, J. Med. Chem., Vol. 41, Part 22, pp. 4216-4223 (Oct 22 1998).	
A69	Hollander AP et al., Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint, Arthritis Rheum. 2001 Jul; 44(7): 1540-4. (Abstract Only).	
A70	Imahashi K. et al., Type IV Phosphodiesterase Inhibitor Suppresses Insulin-Dependent Myocardial Glucose Uptake, Clin Exp Pharmacol Physiol 2001 Apr;28(4), pp. 290-291 (Abstract Only).	
A71	Ishikawa O. et al., Macrophage infiltration in the skin of patients with systemic sclerosis, J. Rheumatology 1992 Aug; 19(8), pp. 1202-1206 (Abstract Only).	
A72	Kapur S. et al., Expression of Nitric Oxide Synthase in Skeletal Muscle, Diabetes, Vol. 46, Nov. 1997, pp. 1691-1700.	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO.	CASE NO.
	09/938,160	P-191
	FILING DATE	GROUP ART UNIT
	AUGUST 23, 2001	NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.		

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A73	5,885,834	3/23/99	Epstein		
A74	5,902,827	5/11/99	Pamukcu et al.		
A75	5,922,595	7/13/99	Fisher et al.		
A76	5,942,520	8/24/99	Pamukcu et al.		
A77	5,948,911	9/7/99	Pamukcu et al.		
A78	5,958,982	9/28/99	Pamukcu et al.		
A79	5,990,117	11/23/99	Pamukcu et al.		
A80	5,998,463	12/7/99	Hulin et al.		
A81	6,008,215	12/28/99	Flockerzi		
A82	6,015,677	1/18/00	Beavo et al.		
A83	6,034,099	3/7/00	Pamukcu et al.		
A84	6,037,345	3/14/00	Pamukcu et al.		
A85	6,046,199	4/4/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
A86	SHO 61-106521	5/24/86	Japan		
A87	WO 01/04099 A1	1/18/01	PCT		
A88	WO 00/12501	3/9/00	PCT	→ US 6,436,952	
A89	WO 00/26201	5/11/00	PCT	→ US 6,376,493	
A90	WO 00/23091	4/27/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
A91	Kelly J. et al., Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors, British Journal of Pharmacology (1998) 124, pp. 129-140.	
A92	Kelly J. et al., Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [³ H]R-(--)-rolipram binding by selective inhibitors, Biochem. J. (1996) 318, pp. 425-436.	
A93	Kumar A. et al., Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors, Indian J Exp Biol 2000 Jan;38(1), pp. 26-30 (Abstract Only)	
A94	Lee MS et al., A comparative immunohistochemical study of lichen planus and discoid lupus erythematosus, Australas J. Dermatol. 1996 Nov.; 37(4): 188-92 (Abstract Only).	
A95	McPherson M.A. et al., A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein, FEBS Letters 464 (1999), pp. 48-52.	
A96	Mery P.F. et al., Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes, Mol. Pharmacology 1995 Jul;48(1), pp. 121-130 (Abstract Only)	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOV 19 2003

Page 5 of 8

FORM PTO-1449

TRADE MARK OFFICE
LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.	09/938,160	CASE NO.
FILING DATE	AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S):	WHITEHEAD ET AL.	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A97	6,046,206	4/4/00	Pamukcu et al.		
A98	6,046,216	4/4/00	Piazza et al.		
A99	6,060,477	5/9/00	Piazza et al.		
A100	6,066,634	5/23/00	Sperl et al.		
A101	6,069,240	5/30/00	Wigler et al.		
A102	6,071,934	6/6/00	Sperl et al.		
A103	6,077,842	6/20/00	Pamukcu et al.		
A104	6,080,540	6/27/00	Wigler et al.		
A105	6,080,742	6/27/00	Germann et al.		
A106	6,080,772	6/27/00	Tang et al.		
A107	6,100,025	8/8/00	Wigler et al.		
A108	6,107,295	8/22/00	Rochus et al.		
A109	6,124,303	9/26/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
A110	WO 00/26208	5/11/00	PCT		
A111	WO 00/27861	5/18/00	PCT		
A112	WO 00/42017	7/20/00	PCT		
A113	WO 00/42018	7/20/00	PCT		
A114	WO 00/42019	7/20/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages; etc.)
A115	Méry, Pierre-François et al., EHNA as an Inhibitor of PDE2: A Pharmacological and Biochemical Study in Cardiac Myocytes, Phosphodiesterase Inhibitors (1996), pp. 81-88.
A116	Michie, A.M. et al., Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitor erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram, Cell Signal 1996 Feb;8(2), pp. 97-110.
A117	Niebauer J. et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Circulation 1999;100, pp. 1830-1835.
A118	Odoux C. et al., Endothelin-1 secretion by alveolar macrophages in systemic sclerosis, Am. J. Respir. Crit. Care Med. 1997 Nov;156(5), pp. 1429-1435 (Abstract Only).
A119	Ostensen M. et al., Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus, Lupus (2001) 10, pp. 135-139.
A120	Piazza G.A. et al., Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis, Cancer Research 55, Jul 15 1995, pp. 3110-3116.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 REV 1-9-2003		SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
		APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A121 6,133,271	10/17/00	Pamukcu et al.		
	A122 6,143,746	11/7/00	Daugan et al.		
	A123 6,143,759	11/7/00	Flockerzi		
	A124 6,143,765	11/7/00	Tang et al.		
	A125 6,143,777	11/7/00	Jonas et al.		
	A126 6,169,090	1/2/01	Dyke et al.		
	A127 6,174,884	1/16/01	Haning et al.		
	A128 6,187,779	2/13/01	Pamukcu et al.		
	A129 6,200,771	3/13/01	Liu et al.		
	A130 6,200,980	3/13/01	Piazza et al.		
	A131 6,207,666	3/27/01	Piazza et al.		
	A132 6,211,177	4/3/01	Sperl et al.		
	A133 6,211,220	4/3/01	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A134 WO 00/42034	7/20/00	PCT		
	A135 WO 00/59890	10/12/00	PCT		
	A136 WO 00/64424	11/2/00	PCT		
	A137 WO 99/65880	11/23/99	PCT		US 6,417,188
	A138 WO 98/19679A1	5/14/98	PCT (Claims Only)		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A139	Reis E. et al., Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice, PNAS 97(23): pp. 12764-12769.
	A140	Rice P.L. et al., Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites, Cancer Research 2001, Feb 15;61(4), pp. 1541-1547 (Abstract Only).
	A141	Soh, Jae-Won et al., Cyclic GMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of c-Jun NH ₂ -Terminal Kinase 1, Clinical Cancer Research Vol. 6, pp. 4136-4141, October 2000.
	A142	Soh, Jae-Won et al., Protein Kinase G Activates the JNK1 Pathway via Phosphorylation of MEKK1, The Journal of Biological Chemistry, Vol. 276, No. 19, pp. 16406-16410 (2001).
	A143	Thompson, W.J. et al., Exisulind Induction of Apoptosis Involves Guanosine 3',5'-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated β -Catenin, Cancer Research 60, pp. 3338-3342, July 1, 2000.
	A144	Tien, Xiao-Ying, et al., Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by cGMP in the Human Colonic Cancer Cell Line, Caco-2, The Journal of Biological Chemistry, Vol. 269, No. 1, pp. 51-54 (1994).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 1.9.3 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION (use several sheets if necessary)	SERIAL NO. 09/938,160	CASE NO. P-191
	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A145	6,232,312	5/15/01	Pamukcu et al.		
A146	6,235,742	5/22/01	Bell et al.		
A147	6,235,776	5/22/01	Pamukcu et al.		
A148	6,235,782	5/22/01	Pamukcu et al.		
A149	6,239,136	5/29/01	Pamukcu et al.		
A150	6,251,904	6/26/01	Bunnage et al.		
A151	6,255,303	7/3/01	Sterk et al.		
A152	6,255,456	7/3/01	Fisher et al.		
A153	6,258,833	7/10/01	Martins et al.		
A154	6,268,372	7/31/01	Pamukcu et al.		
	—				

RECEIVED
TECH. SER. 117 NOV 26 2003
117, 600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
A155	WO 98/17668	4/30/98	PCT	→ US	6,130,223
A156	WO 98/14448	4/9/98	PCT	→ US	6,265,577
A157	WO 98/06722	2/19/98	PCT	→ US	6,110,920
A158	WO 97/24334	7/10/97	PCT	→ US	6,166,219
A159	WO 97/03985	2/6/97	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
A160	Tsukahara T et al., Cytophagic histiocytic panniculitis in systemic lupus erythematosus, Hiroshima J. Med. Sci., 1995 Mar; 44(1): 13-6 (Abstract Only).
A161	Waddel W. R. et al., Sulindac for Polyposis of the Colon, The American Journal of Surgery, Vol. 157, Jan. 1989, pp. 175-179.
A162	Waddel W. R. et al., Sulindac for Polyposis of the Colon, Journal of Surgical Oncology, 24: pp. 83-87 (1983).
A163	Weyand CM and Goronzy JJ, HLA polymorphisms and T cells in rheumatoid arthritis, Int. Rev. Immunol. 1999; 19(1-2):37-39 (Abstract Only).
A164	Wilder R.L. et al., Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus?, Ann. NY Acad. Sci 1999 June 22:876, pp. 14-31 (Abstract Only).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 NOV 19 2003 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO. 09/938,160	CASE NO. P-191
	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
	A165 WO 97/03675	2/6/97	PCT			
	A166 WO 94/29277	11/22/94	PCT			
	A167 WO 93/07149	4/15/93	PCT			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next
communication to applicant.